CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Corvus Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$9.65+0.13 (+1.37%)

Close on Oct 19, 2026

Market cap: $891.35M
P/E (TTM): –
Dividend yield: –

Corvus Pharmaceuticals, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31
Research & Development	34	19	17	24	29	32	38	39	46	29	11	–
General & Administrative	9.25	8.16	6.88	8.10	9.52	12	11	11	10	7.62	2.42	–
Operating Expenses	43	28	23	33	39	44	49	49	57	37	14	–
Total Costs & Expenses	–	–	–	–	–	–	–	–	–	37	14	–
Operating Income	-43	-28	-23	-33	-39	-44	-49	-49	-57	-37	-14	–
Income from Equity Investments	-1.96	-3.20	-5.28	-10	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	0.01	–	0.02	–	–	–	–	–	–	–	–
Pretax Income	-13	-59	-22	-31	-43	-6.00	-47	-47	-56	-36	-31	-0.16
Income Tax Expense	0	0	0	0	0	0	0	0	0	0	0	–
Net Income incl. Noncontrolling Interests	-15	-62	-27	-41	-43	-6.00	-47	-47	-56	-36	-31	–
Net Income	-15	-62	-27	-41	-43	-6.00	-47	-47	-56	-36	-31	–
Net Income to Common	-15	-62	-27	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	-0.19	-1.02	-0.56	-0.89	-1.03	-0.20	-1.59	-1.71	-2.72	-2.36	-83.86	–
EPS (Diluted)(per share)	-0.53	-1.02	-0.56	-0.89	-1.03	-0.20	-1.59	-1.71	-2.72	-2.36	-83.86	–
Shares Outstanding (Basic, Weighted)(shares)	79	61	48	47	42	29	29	28	20	15	0.37	–
Shares Outstanding (Diluted, Weighted)(shares)	80	61	48	47	42	29	29	28	20	15	0.37	–
EBITDA	-43	-27	-23	-32	-38	-43	-48	-48	-56	-36	-14	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -32.6%

Financial strength

Current ratio: 16.16
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 138.3%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 3.96
Dividend yield: –